Drug & intervention

docetaxel

RxCUI 72962

Clinical trials1,091

Recruiting97

Related conditions20

Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Background context

docetaxel

Wikidata Q27126905 ↗

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown

Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO TrialNCT07698535 · 2026-10-01

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)NCT07723248 · 2026-08-03

A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D MutationNCT07668752 · 2026-07-27

Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBCNCT07797218 · 2026-07-01

Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)NCT07660094 · 2026-06-15

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.NCT07333066 · 2026-06-05

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate CancerNCT07590934 · 2026-06-03

A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung CancerNCT07459751 · 2026-05-27

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy FailureNCT07528274 · 2026-05-01

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationNCT07566052 · 2026-04-28

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate CancerNCT07365995 · 2026-04-22

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerNCT07518173 · 2026-04-21

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast CancerNCT07402473 · 2026-03-26

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung CancerNCT07416994 · 2026-03-18

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerNCT07287150 · 2026-03-11

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)NCT06951646 · 2026-03-10

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerNCT07441460 · 2026-03-06

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast CancerNCT07377643 · 2026-02-10

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate CancerNCT07225946 · 2025-12-19

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedNCT06908993 · 2025-12-09

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCNCT06908304 · 2025-12-08

WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLCNCT07330050 · 2025-12-01

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE TrialNCT06931340 · 2025-12-01

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674 · 2025-11-28

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerNCT07001618 · 2025-11-17

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast CancerNCT07220135 · 2025-11-14

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsNCT07291037 · 2025-10-31

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung CancerNCT07381829 · 2025-10-27

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCNCT07246863 · 2025-10-07

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint InNCT06745908 · 2025-10-01

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381 · 2025-09-24

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast CancerNCT07017673 · 2025-07-25

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)NCT07070440 · 2025-07-16

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)NCT06863272 · 2025-07-03

A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerNCT06891833 · 2025-06-05

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseNCT06592924 · 2025-05-28

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)NCT06780098 · 2025-05-28

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)NCT06616584 · 2025-05-22

AK129 Combination Therapy for Advanced Solid TumorsNCT06943820 · 2025-05-21

Conditions being studied

Research locations

New YorkNew York, United States143 HoustonTexas, United States137 MadridSpain126 ChicagoIllinois, United States121 Los AngelesCalifornia, United States120 BaltimoreMaryland, United States116 BostonMassachusetts, United States108 NashvilleTennessee, United States104 St LouisMissouri, United States104 DetroitMichigan, United States103 BarcelonaSpain99 SeattleWashington, United States98

Leading sponsors

Hoffmann-La Roche53 National Cancer Institute (NCI)39 Merck Sharp & Dohme LLC26 Sanofi23 Eli Lilly and Company22 SWOG Cancer Research Network21 Alliance for Clinical Trials in Oncology18 Hellenic Oncology Research Group18 M.D. Anderson Cancer Center17 AstraZeneca16 Bristol-Myers Squibb14 SCRI Development Innovations, LLC14 Fudan University13 Pfizer13 GlaxoSmithKline12

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.